Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FedEx Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.60B), while FedEx Corporation trades at $326.06 (market cap $76.28B). The key difference: FedEx Corporation is far larger — about 2.6× Alnylam Pharmaceuticals, Inc.'s market cap, and FedEx Corporation pays a 1.51% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FDX | |
|---|---|---|
Market Cap | $29.60B | $76.28B |
Sector | Health | Industrials |
52-Week High | $491.22 | $338.75 |
52-Week Low | $205.48 | $180.51 |
Enterprise Value | $27.56B | $105.91B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
FedEx (FDX) trades at $326.25, up 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $360.27. Recent earnings beats in Q4 2025 and Q1 2026 highlight strong profitability, with a net income margin of 4.68% and ROE of 14.82%. The company's Network 2.0 initiative aims for $2 billion in annual savings, driving efficiency gains amid a shift to premium logistics services.
The stock offers upside potential from cost-cutting and freight recovery, but faces risks from competitive pressures and economic sensitivity. Analysts are predominantly bullish (57% buy ratings), though elevated RSI levels suggest near-term overbought conditions. Long-term growth hinges on execution of margin improvements and volume normalization in the LTL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
